hotspot -WSS

hotspot

author：explore 2025-08-12 11:27:57 - browse：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Erich Jarvis studies song birds to learn about human stuttering

WSS

CRISPR technology availability, affordability needs to be expanded

Live blog: Hearing on CRISPR

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Kidney transplant patients stopped immunosuppressants in trial

Diabetes management: Digital health tools fall short, study says

focus

hotspot

hotspot

New air purifier tech could be key to improving indoor air quality

Adam's Take: Intra

Medical leaders decry Supreme Court decision on affirmative action

Prime Medicine says its gene editing passes test in monkeys

Drug repurposing or repositioning? The language matters

Gene therapy’s promise and the high cost of hope

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Diabetes management: Digital health tools fall short, study says

Sports medicine is finally prioritizing gender equality

After Sarepta trial failure, Duchenne families brace for more debate

hotspot

Inari Medical to buy amputation prevention company LimFlow

Live blog: Hearing on CRISPR

Medicare Advantage insurers pressure Biden for bigger payments

Pfizer, Moderna say biotech, pharma drug development is a sprint

Asbestos ban is immediate, but health effects will linger for decades

Pfizer, Moderna say biotech, pharma drug development is a sprint

entertainment

focus

knowledge

explore